| Date | Title | Description |
| 07.07.2026 | RoosterBio and Qkine Partner to Deliver a Single-Source Platform to U.S. Customers | RoosterBio and Qkine Partner recently announced a partnership to deliver a single-source platform of cells, media, and growth factors to U.S. customers.
By bringing together high-quality cells, bioprocess media, and recombinant growth facto... |
| 26.05.2026 | Game-changing accelerator which has helped life science start-ups raise £120m welcomes new cohort | Six exciting early-stage ventures secure coveted spots on Babraham Research Campus’ Accelerate@Babraham pre-seed company support programme.
Cambridge, UK, 26th May 2026: Babraham Research Campus is delighted to announce the 2026 Accelerate@... |
| 27.01.2026 | Qkine Limited and Akron Bio Announce Strategic Partnership | - |
| 08.10.2025 | Qkine launches cell therapy grade recombinant proteins to support next-generation therapies | Cambridge, UK – Qkine, Ltd., a specialist bioactive protein manufacturer with its core technology developed at the University of Cambridge, today announced the launch of its Cell Therapy Grade proteins, engineered to support the stringent r... |
| 01.10.2025 | Qkine launches cell therapy grade recombinant proteins to support next-generation therapies | - |
| 12.01.2025 | Cultivated Meat: The Future of Food on the Horizon | The world is changing. Our food systems are at a crossroads. Population growth, environmental challenges, and the quest for sustainable protein sources are pushing us toward a new frontier: cultivated meat. This innovation offers a tantaliz... |
| 06.01.2025 | Qkine Launches Animal-Origin-Free & Food-Grade Growth Factors for Cellular Agriculture | Qkine, a producer of growth factors for cultivated meat and cellular agriculture, has launched a new product range.
The new growth factors are animal-origin-free, food-grade, and subject to extensive quality analysis. They are produced usin... |
| 07.11.2024 | Qkine announces a new sales distribution agreement in Türkiye with distributor Pitagen | Qkine, a leading manufacturer of high purity bioactive proteins, is pleased to announce its new sales distribution agreement with leading cell biology and stem cell reagent supplier Pitagen.
About Pitagen
Pitagen is a company based in Istan... |
| 06.11.2024 | Qkine announces a new UK & Ireland sales distribution agreement with SLS | Qkine, a leading manufacturer of high purity bioactive proteins, is pleased to announce its UK/IE sales distribution agreement with SLS.
"We are thrilled to partner with SLS who provide the scale Qkine needs in order to reach and suppo... |
| 06.09.2024 | Qkine expands senior leadership | Qkine expands senior leadership with the appointment of Rob Nixon, Commercial Director, and Paul Grafham, Chief Financial Officer.
Qkine is delighted to announce the appointment of Rob Nixon to its leadership team as Commercial Director and... |
| 28.07.2023 | Meet the founder: ORF Genetics’ Dr. Björn Örvar on why barley could unlock the potential of cultivated meat | Growth factors—signaling proteins used to stimulate cell growth and differentiation in cultivated meat production—come with a hefty price tag, putting pressure on firms to express them more efficiently in everything from fruit flies to micr... |
| 26.07.2023 | Qkine announces collaboration with Sartorius | Qkine, a manufacturer of animal-free, highly bioactive, and innovative proteins, announces its collaboration with Sartorius, a global life science group, to supply growth factors and cytokines for stem cell and organoid research, as part of... |
| 06.07.2023 | Qkine and Sartorius Partnership Delivers a Complete Workflow Solution for the Analysis of Advanced Cell Models | Sartorius to commercialise Qkine growth factors and cytokines as part of a complete workflow solution for stem cell and organoid research
Cell type-specific application data on Sartorius instruments streamline process and speed up time to r... |
| 07.02.2023 | #21toWatch announces shortlist of next generation of Cambridge game-changers set for future success | cofinitive have announced the shortlist for #21toWatch 2023 which this year contains an eclectic mix of industries – biotech, cleantech, agritech, construction, automotive, deep learning, marine, life sciences, AI – all sharing the same mis... |
| 12.01.2023 | Oxford Innovation invest in Qkine’s £4.3 million fund raise | Oxford Innovation EIS Growth Fund and OION Angels invest 14% of Qkine’s latest £4.3 million fund raise which was co-led by Parkwalk Advisors Ltd and Downing Ventures. |
| 23.12.2022 | Qkine – raises £4.3m in latest funding round | We’re delighted to announce our recent investment in Qkine, as part of a £4.3m funding round. The University of Cambridge spin-out has designed a proprietary refolding technology and protein purification technique to produce high quality gr... |
| 15.12.2022 | Qkine Raises Over £4 Million to Scale Manufacturing, R&D and Commercial Functions | Qkine Ltd, a manufacturer of animal-free, highly bioactive, and innovative proteins and growth factors for life science applications, announces the close of its oversubscribed funding raise, having secured £4.3M. The round, which was co-led... |
| 15.12.2022 | Qkine Raises Over £4M in Funding | Qkine, a Cambridge, UK-based manufacturer of animal-free, bioactive, and innovative proteins and growth factors for life science applications, raised £4M in funding.
The round was led by Parkwalk Advisors Ltd and Downing Ventures.
The compa... |
| 15.12.2022 | Qkine raises £4.3m scale-up capital and prepares HQ move | - |
| 08.10.2021 | Qkine appoints Japanese distribution partner MBL to extend global availability of stem cell and organoid culture reagents | Qkine appoints Japanese distribution partner MBL to extend global availability of stem cell and organoid culture reagents
08-10-2021
Qkine – UK-based specialist developer and manufacturer of proteins for stem cell and organoid culture – has... |
| 09.06.2020 | Qkine secures £1.5m Series A | Qkine – a specialist developer and manufacturer of proteins for stem cell, organoid and regenerative medicine applications – today announced the successful closure of a £1.5 million Series A investment round to accelerate the global scale-u... |
| 08.06.2020 | Qkine secures £1.5M Series A funding from leading life science investors | Qkine today announced the successful closure of a £1.5M Series A investment round to accelerate the global scale-up of its commercial operations and make key hires to its leadership team.
Qkine – a specialist developer and manufacturer of p... |
| 08.06.2020 | Qkine secures £1.5M Series A funding from leading life science investors | Qkine secures £1.5M Series A funding from leading life science investors
08-06-2020
Qkine today announced the successful closure of a £1.5M Series A investment round to accelerate the global scale-up of its commercial operations and make ke... |
| 03.06.2019 | Qkine secures additional £550K to extend development of R&D pipeline and accelerate commercialisation of product portfolio | Qkine secures additional £550K to extend development of R&D pipeline and accelerate commercialisation of product portfolio
03-06-2019
Qkine, specialist manufacturer of proteins for stem cell, organoid and regenerative medicine applicati... |
| 03.06.2019 | Qkine Raises Additional £550K in Funding | Qkine, a Cambridge, England, UK-based specialist manufacturer of proteins for stem cell, organoid and regenerative medicine applications, closed a further £550K in funding.
The round was led by Cambridge Enterprise and five angel investors ... |
| 03.06.2019 | Qkine secures additional £550K to extend development of R&D pipeline and accelerate commercialisation of product portfolio | Qkine, specialist manufacturer of proteins for stem cell, organoid and regenerative medicine applications has closed a further round of investment. The £550k funding round was led by Cambridge Enterprise and five angel investors – all of wh... |
| 23.04.2018 | Qkine backed by Cambridge Enterprise and a quintet of angels | Qkine backed by Cambridge Enterprise and a quintet of angels
23-04-2018
University of Cambridge spin-out Qkine has closed its seed investment round supported by Cambridge Enterprise, the commercialisation arm of the University, and a team o... |
| - | Qkine – £1.5M series A funding from leading life science investors | Qkine secures £1.5M series A funding from leading life science investors to accelerate global scale-up and make key hires to leadership team |
| - | Qkine | “High purity, bioactive recombinant growth factor and cytokine proteins for stem cell, organoid and regenerative medicine.” |
